Abstract
Adherence to consensus guidelines for cancer care may vary widely across health care settings and contribute to differences in cancer outcomes. For some women with breast cancer, omission of adjuvant chemotherapy or delays in its initiation may contribute to differences in cancer recurrence and mortality. We studied adjuvant chemotherapy use among women with stage II or stage III, hormone receptor–negative breast cancer to understand health system and socio-demographic correlates of underuse and delayed adjuvant chemotherapy. We used Surveillance Epidemiology and End Results (SEER)-Medicare linked data to examine the patterns of care for 6,678 women aged 65 and older diagnosed with stage II or stage III hormone receptor–negative breast cancer in 1994–2002, with claims data through 2007. Age-stratified logistic regression was employed to examine the potential role of socio-demographic and structural/organizational health services characteristics in explaining differences in adjuvant chemotherapy initiation. Overall utilization of guideline-recommended adjuvant chemotherapy peaked at 43% in this population. Increasing age, higher co-morbidity burden, and low-income status were associated with lower odds of chemotherapy initiation within 4 months, whereas having positive lymph nodes, more advanced disease, and being married were associated with higher odds (P < 0.05). Health system–related structural/organizational characteristics and race/ethnicity offered little explanatory insight. Timely initiation of guideline-recommended adjuvant chemotherapy was low, with significant variation by age, income, and co-morbidity status. Based on these findings, future studies should seek to explore the more nuanced reasons why older women do not receive chemotherapy and why delays in care occur.
Similar content being viewed by others
References
Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LAG, Schrag D, Jamison PM, Jemal A, Wu XC et al (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer Treatment. J Natl Cancer Inst 97(19):1407–1427
Lund MJ, Brawley OP, Ward KC, Young JL, Gabram SS, Eley JW (2008) Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat 109(3):545–557
Zapka JG, Taplin SH, Solberg LI, Manos MM (2003) A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. Cancer Epidemiol Biomarkers Prev 12(1):4–13
Davis D, Evans M, Jadad A, Perrier L, Rath D, Ryan D, Sibbald G, Straus S, Rappolt S, Wowk M et al (2003) The case for knowledge translation: shortening the journey from evidence to effect. BMJ 327(7405):33–35
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295(21):2492–2502
Anders C, Carey LA (2008) Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22(11):1233–1239 discussion 1239–1240, 1243
Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26(1):1–10
Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139
NIH consensus conference (1991) Treatment of early-stage breast cancer. JAMA 265(3):391–395
Desch CE, McNiff KK, Schneider EC, Schrag D, McClure J, Lepisto E, Donaldson MS, Kahn KL, Weeks JC, Ko CY (2008) American society of clinical oncology/national comprehensive cancer network quality measures. J Clin Oncol 26(21):3631–3637
Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP et al (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360(20):2055–2065
Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O (2004) Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q 82(4):581–629
Bowen S, Zwi AB (2005) Pathways to “evidence-informed” policy and practice: a framework for action. PLoS Med 2(7):e166
Birkmeyer NJ, Goodney PP, Stukel TA, Hillner BE, Birkmeyer JD (2005) Do cancer centers designated by the National Cancer Institute have better surgical outcomes? Cancer 103(3):435–441
Gooden KM, Howard DL, Carpenter WR, Carson AP, Taylor YJ, Peacock S, Godley PA (2008) The effect of hospital and surgeon volume on racial differences in recurrence-free survival after radical prostatectomy. Med Care 46(11):1170–1176
Morris AM, Billingsley KG, Hayanga AJ, Matthews B, Baldwin LM, Birkmeyer JD (2008) Residual treatment disparities after oncology referral for rectal cancer. J Natl Cancer Inst 100(10):738–744
Talcott JA, Spain P, Clark JA, Carpenter WR, Do YK, Hamilton RJ, Galanko JA, Jackman A, Godley PA (2007) Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer 109(8):1599–1606
Onega T, Duell EJ, Shi X, Demidenko E, Gottlieb D, Goodman DC (2009) Influence of NCI-cancer center attendance on mortality in lung, breast, colorectal, and prostate cancer patients. Med Care Res Rev 66(5):542–560
Anderson RT, Kimmick GG, Camacho F, Whitmire JT, Dickinson C, Levine EA, Torti FM, Balkrishnan R (2008) Health system correlates of receipt of radiation therapy after breast-conserving surgery: a study of low-income medicaid-enrolled women. Am J Manag Care 14(10):644–652
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications and generalizability to the United States elderly population. Med Care 40(8 Suppl):IV-3-18
Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS (2006) Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 24(18):2757–2764
Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB (2002) Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40(8 Suppl):1 IV-55-61
Schroen AT, Lohr ME (2009) Travel distance to mammography and the early detection of breast cancer. Breast J 15(2):216–217
Nattinger AB, Kneusel RT, Hoffmann RG, Gilligan MA (2001) Relationship of distance from a radiotherapy facility and initial breast cancer treatment. J Natl Cancer Inst 93(17):1344–1346
Shea AM, Curtis LH, Hammill BG, DiMartino LD, Abernethy AP, Schulman KA (2008) Association between the medicare modernization act of 2003 and patient wait times and travel distance for chemotherapy. JAMA 300(2):189–196
Meden T, St John-Larkin C, Hermes D, Sommerschield S (2002) MSJAMA. Relationship between travel distance and utilization of breast cancer treatment in rural northern Michigan. JAMA 287(1):111
Schroen AT, Brenin DR, Kelly MD, Knaus WA, Slingluff CL Jr (2005) Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients. J Clin Oncol 23(28):7074–7080
Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL (2002) Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 40(8):IV-19-25
Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D (2007) A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 17(8):584–590
Andre F, Pusztai L (2006) Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 3(11):621–632
Singletary SE, Connolly JL (2006) Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56(1):37–47 quiz 50–31
Banerjee M, George J, Yee C, Hryniuk W, Schwartz K (2007) Disentangling the effects of race on breast cancer treatment. Cancer 110(10):2169–2177
Haas JS, Earle CC, Orav JE, Brawarsky P, Keohane M, Neville BA, Williams DR (2008) Racial segregation and disparities in breast cancer care and mortality. Cancer 113(8):2166–2172
Schootman M, Jeffe DB, Lian M, Gillanders WE, Aft R (2009) The role of poverty rate and racial distribution in the geographic clustering of breast cancer survival among older women: a geographic and multilevel analysis. Am J Epidemiol 169(5):554–561
Bao Y, Fox SA, Escarce JJ (2007) Socioeconomic and racial/ethnic differences in the discussion of cancer screening: “between-” versus “within-” physician differences. Health Serv Res 42(3 Pt 1):950–970
Bhargava A, Du XL (2009) Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer 115(13):2999–3008
Pagano M, Gauvreau K (2000) Principles of biostatistics, 2nd edn. Duxbury Press, Pacific Grove
Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia
Wooldridge JM (2006) Introductory econometrics—a modern approach. Thomson-Southwestern, Mason
Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS (2003) Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med 138(2):90–97
Du X, Goodwin JS (2001) Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol 19(5):1455–1461
Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24(18):2750–2756
Passage KJ, McCarthy NJ (2007) Critical review of the management of early-stage breast cancer in elderly women. Intern Med J 37(3):181–189
Wildiers H, Brain EG (2005) Adjuvant chemotherapy in elderly patients with breast cancer: where are we? Curr Opin Oncol 17(6):566–572
Giordano SH, Fang S, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS (2008) Use of intravenous bisphosphonates in older women with breast cancer. Oncologist 13(5):494–502
Owusu C, Lash TL, Silliman RA (2007) Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat 102(2):227–236
Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24(9):1357–1362
Enewold L, Zhou J, McGlynn KA, Anderson WF, Shriver CD, Potter JF, Zahm SH, Zhu K (2011) Racial variation in breast cancer treatment among department of defense beneficiaries. Cancer doi: 10.1002/cncr.26346
Chaudhry R, Goel V, Sawka C (2001) Breast cancer survival by teaching status of the initial treating hospital. CMAJ 164(2):183–188
Hebert-Croteau N, Brisson J, Lemaire J, Latreille J, Pineault R (2005) Investigating the correlation between hospital of primary treatment and the survival of women with breast cancer. Cancer 104(7):1343–1348
Laliberte L, Fennell ML, Papandonatos G (2005) The relationship of membership in research networks to compliance with treatment guidelines for early-stage breast cancer. Med Care 43(5):471–479
Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI (2006) Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 99(3):313–321
Acknowledgments
Funding was provided by Dr. Wheeler’s National Research Service Award (NRSA) Predoctoral Traineeship from the Agency for Healthcare Research and Quality (AHRQ) sponsored by the Cecil G. Sheps Center for Health Services Research, UNC at Chapel Hill, Grant No. 5-T-32 HS000032-20, and a pilot grant, Grant No. 2KR50906 (PI: Wheeler) from the North Carolina Translational and Clinical Sciences (NC TraCS) Institute, Clinical and Translational Science Award (CTSA) Number UL1RR025747 from the National Center for Research Resources, National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wheeler, S.B., Carpenter, W.R., Peppercorn, J. et al. Predictors of timing of adjuvant chemotherapy in older women with hormone receptor–negative, stages II–III breast cancer. Breast Cancer Res Treat 131, 207–216 (2012). https://doi.org/10.1007/s10549-011-1717-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-011-1717-6